GB0713192D0 - Anti-tumour methods - Google Patents

Anti-tumour methods

Info

Publication number
GB0713192D0
GB0713192D0 GBGB0713192.3A GB0713192A GB0713192D0 GB 0713192 D0 GB0713192 D0 GB 0713192D0 GB 0713192 A GB0713192 A GB 0713192A GB 0713192 D0 GB0713192 D0 GB 0713192D0
Authority
GB
United Kingdom
Prior art keywords
tumour
methods
tumour methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0713192.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VERENIGING HET NEDERLANDS KANKER INSTITUUT
Original Assignee
VERENIGING HET NEDERLANDS KANKER INSTITUUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VERENIGING HET NEDERLANDS KANKER INSTITUUT filed Critical VERENIGING HET NEDERLANDS KANKER INSTITUUT
Priority to GBGB0713192.3A priority Critical patent/GB0713192D0/en
Publication of GB0713192D0 publication Critical patent/GB0713192D0/en
Priority to PCT/GB2008/002224 priority patent/WO2009007677A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0713192.3A 2007-07-06 2007-07-06 Anti-tumour methods Ceased GB0713192D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0713192.3A GB0713192D0 (en) 2007-07-06 2007-07-06 Anti-tumour methods
PCT/GB2008/002224 WO2009007677A2 (en) 2007-07-06 2008-06-27 Anti-tumour methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0713192.3A GB0713192D0 (en) 2007-07-06 2007-07-06 Anti-tumour methods

Publications (1)

Publication Number Publication Date
GB0713192D0 true GB0713192D0 (en) 2007-08-15

Family

ID=38440558

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0713192.3A Ceased GB0713192D0 (en) 2007-07-06 2007-07-06 Anti-tumour methods

Country Status (2)

Country Link
GB (1) GB0713192D0 (en)
WO (1) WO2009007677A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764234C (en) 2009-06-04 2019-03-12 The Governors Of The University Of Alberta Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(adp-ribose) polymerase and uses thereof
EP2753716B1 (en) 2011-09-08 2017-11-01 Yeda Research and Development Co. Ltd. Novel risk biomarkers for lung cancer
CN106995840B (en) * 2017-03-20 2020-05-05 山东师范大学 Method for detecting activity of thymine DNA glycosylase based on double-signal amplification strategy mediated by cyclic enzyme repair
CN110408694A (en) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 Temozolomide is assessed in the new method of the sensibility for the treatment of Patients with gliomas
CN109321658B (en) * 2018-11-23 2021-09-07 浙江大学 Kit for detecting susceptibility of cervical cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2092083A2 (en) * 2006-10-20 2009-08-26 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer

Also Published As

Publication number Publication date
WO2009007677A3 (en) 2009-11-26
WO2009007677A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
GB0706709D0 (en) Methods
GB0725299D0 (en) Portaboard
AP2010005314A0 (en) Nanodispersian
HK1132673A1 (en) Novel methods
GB0718160D0 (en) Methods
GB2448989B (en) Area-partitioning
GB0713192D0 (en) Anti-tumour methods
EP2161998A4 (en) Novel methods
GB0715502D0 (en) Methods
GB0714842D0 (en) Methods
GB0707735D0 (en) Methods
GB0709749D0 (en) Juglr
GB0719252D0 (en) Methods
GB0713673D0 (en) Methods
GB0806623D0 (en) My leener
GB0713910D0 (en) Lensun
GB0703800D0 (en) Fascines
GB0724222D0 (en) Methods
GB0712401D0 (en) Methods
GB0700966D0 (en) Methods
GB0715542D0 (en) Methods
GB0713281D0 (en) Methods
GB0701417D0 (en) Methods
GB0722035D0 (en) Methods
GB0714265D0 (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)